PARP1 and ovarian carcinoma: These findings suggest that alisertib may be used in combination with PARPis to sensitize PARPi-resistant or otherwise weakly sensitive ovarian carcinoma cells to PARP inhibition, although we cannot rule out the possibility that alisertib treatment decreases ovarian carcinoma cell viability because other AURKA-regulated functions not related to DNA repair, are altered.